Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy

OBJECTIVE: To determine whether rituximab 375 mg/m(2) was efficacious in patients with immunoglobulin M (IgM) anti-myelin–associated glycoprotein antibody demyelinating neuropathy (IgM anti-MAG demyelinating neuropathy). METHODS: Fifty-four patients with IgM anti-MAG demyelinating neuropathy were en...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Léger, Jean-Marc, Viala, Karine, Nicolas, Guillaume, Créange, Alain, Vallat, Jean-Michel, Pouget, Jean, Clavelou, Pierre, Vial, Christophe, Steck, Andreas, Musset, Lucile, Marin, Benoit
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3721095/
https://ncbi.nlm.nih.gov/pubmed/23667063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318296e92b
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires